Race of GLPS: Impact on Weight and Glycemic Control on Type 2 Diabetes with Semaglutide Versus Liraglutide
Keywords:
Semaglutide, Liraglutide, Weight loss, Glycemic controlAbstract
OBJECTIVES
Semaglutide is a glucagon-like peptide-1 receptor agonist that improves glycemic control and reduces body weight in patients with type 2 diabetes. This study aimed to evaluate the effect of Semaglutide with standard Metformin on glycemic control and BMI after 3 and 6 months of treatment. Additionally, we compared the glycemic control and weight benefits of Semaglutide vs. liraglutide.
METHODOLOGY
This longitudinal cohort study was conducted in a general practice clinic in Clifton and a family medicine health center in Ziauddin University, Karachi from April 2022 till April 2023. We enrolled 128 patients with type 2 diabetes who were treated with metformin alone. Patients received Semaglutide 2mg once weekly in addition to standard metformin 1gm bid for 6 months. HbA1C and BMI were measured at baseline, 3 months, and 6 months. We compared the glycemic control and weight loss of Semaglutide with a cohort of participants taking Liraglutide over a period of 6 months in the same catchment area in 2021 to determine which drug has an edge over the other.
RESULTS
Semaglutide was superior to Liraglutide in controlling sugars (HbA1c% reduction 1.13 vs 0.94) as well as in weight loss (10.6 vs 6.2kg) respectively. Single sample t-test showed a statistically significant difference from the hypothetical mean of HbA1C <6.5% (p-value <0.00) Paired t-test showed a strong correlation between initial weight and after 6 months’ weight and HbA1C respectively. (p-value <0.00 & 0.004).
CONCLUSION
Semaglutide has proven to be substantially beneficial in reducing weight (10.6kgs) and achieving optimal glycemic control (1.13% HbA1C reduction) over the 6-month study period. Semaglutide is superior to Liraglutide in controlling sugars and weight.
Downloads
Metrics
References
Celik O, Yildiz BO. Obesity and physical exercise. Minerva Endocrinology. 2021;46(2). Doi:10.23736/s2724-6507.20.03361-1
Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism. 2022;133:155217
Stone S, Drobycki N, Johnson M. Abstract NS5: Use of a Multidisciplinary Approach to Successfully Improve Inpatient Diabetes Self-Management Education and Diabetes Medication Reconciliation at Discharge for Persons With Diabetes and Stroke at a Major Academic Medical Center. Stroke. 2020;51(Suppl_1). Doi: 10.1161/str.51.suppl_1.ns5
Jakicic JM, Apovian CM, Barr-Anderson DJ, Courcoulas AP, Donnelly JE, Ekkekakis P, et al. Physical Activity and Excess Body Weight and Adiposity for Adults. American College of Sports Medicine Consensus Statement. Medicine & Science in Sports & Exercise. 2024;56(10):2076-91
Røder ME. Clinical potential of treatment with semaglutide in type 2 diabetes patients. Drugs Context. 2019;8:212585-
Williams DM, Staff M, Bain SC, Min T. Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity. touchREV Endocrinol. 2022;18(1):43-8
Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord. 2022;23(3):521-39
Krieger J-P. Intestinal glucagon-like peptide-1 effects on food intake: Physiological relevance and emerging mechanisms. Peptides. 2020;131:170342
Ryan DH, Lingvay I, Colhoun HM, Deanfield J, Emerson SS, Kahn SE, et al. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. American Heart Journal. 2020;229:61-9
Husain M, Bain SC, Holst AG, Mark T, Rasmussen S, Lingvay I. Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. Cardiovasc Diabetol. 2020;19(1):156-
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002
Shu Y, He X, Wu P, Liu Y, Ding Y, Zhang Q. Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system. Front Public Health. 2022;10:996179-
Niman S, Hardy J, Goldfaden RF, Reid J, Sheikh-Ali M, Sutton D, et al. A Review on the Efficacy and Safety of Oral Semaglutide. Drugs R D. 2021;21(2):133-48
Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021;12:645563-
Chao AM, Tronieri JS, Amaro A, Wadden TA. Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations. Drug Des Devel Ther. 2022;16:4449-61
Kane MP, Triplitt CL, Solis-Herrera CD. Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists. Am J Health Syst Pharm. 2021;78(7):556-67.
Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, Sørrig R, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022;327(2):138-50
Raff E, Hramiak I, Mann JF, Frandsen KB, Daniels G, Kristensen P, et al. Liraglutide and Renal Outcomes in Type 2 Diabetes: Results of the LEADER Trial. Canadian Journal of Diabetes. 2017;41(5):S5
Pavlou V, Cienfuegos S, Lin S, Ezpeleta M, Ready K, Corapi S, et al. Effect of Time-Restricted Eating on Weight Loss in Adults With Type 2 Diabetes: A Randomized Clinical Trial. JAMA Netw Open. 2023;6(10):e2339337-e
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2022;376:o109-o
Liu L, Chen J, Wang L, Chen C, Chen L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol (Lausanne). 2022;13:1043789-
Wharton S, Calanna S, Davies M, Dicker D, Goldman B, Lingvay I, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(1):94-105
Handelsman Y, Butler J, Bakris GL, DeFronzo RA, Fonarow GC, Green JB, et al. Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. Journal of Diabetes and its Complications. 2023;37(2):108389
Pati S, Pati S, Akker Mvd, Schellevis FFG, Jena S, Burgers JS. Impact of comorbidity on health-related quality of life among type 2 diabetic patients in primary care. Prim Health Care Res Dev. 2020;21:e9-e.
Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102-.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Noha Hafeez, Fatima Jehanghir, Aroosa Altaf, Huma Akbar Jafri, Tariq Adnan, Faiza Rani Ahmed, Naureen Kazim
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
